Literature DB >> 20015875

Early hemorrhagic death before starting therapy in acute promyelocytic leukemia: association with high WBC count, late diagnosis and delayed treatment initiation.

Massimo Breccia, Roberto Latagliata, Laura Cannella, Clara Minotti, Giovanna Meloni, Francesco Lo-Coco.   

Abstract

Entities:  

Mesh：

Year:  2009        PMID： 20015875      PMCID： PMC2864399          DOI： 10.3324/haematol.2009.017962

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  7 in total

1.  Severe hemorrhagic complications during remission induction therapy for acute promyelocytic leukemia: incidence, risk factors, and influence on outcome.

Authors:  Masamitsu Yanada; Tadashi Matsushita; Norio Asou; Yuji Kishimoto; Motohiro Tsuzuki; Yasuhiro Maeda; Kentaro Horikawa; Masaya Okada; Shigeki Ohtake; Fumiharu Yagasaki; Tadashi Matsumoto; Yukihiko Kimura; Katsuji Shinagawa; Masako Iwanaga; Yasushi Miyazaki; Ryuzo Ohno; Tomoki Naoe
Journal:  Eur J Haematol       Date:  2007-01-16       Impact factor: 2.997

2.  Early haemorrhagic morbidity and mortality during remission induction with or without all-trans retinoic acid in acute promyelocytic leukaemia.

Authors:  E Di Bona; G Avvisati; G Castaman; M Luce Vegna; V De Sanctis; F Rodeghiero; F Mandelli
Journal:  Br J Haematol       Date:  2000-03       Impact factor: 6.998

3.  Curative strategies in acute promyelocytic leukemia.

Authors:  Martin S Tallman; Jessica K Altman
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2008

Review 4.  Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.

Authors:  Miguel A Sanz; David Grimwade; Martin S Tallman; Bob Lowenberg; Pierre Fenaux; Elihu H Estey; Tomoki Naoe; Eva Lengfelder; Thomas Büchner; Hartmut Döhner; Alan K Burnett; Francesco Lo-Coco
Journal:  Blood       Date:  2008-09-23       Impact factor: 22.113

5.  Acute promyelocytic leukemia: recent advances in diagnosis and management.

Authors:  Francesco Lo-Coco; Emanuele Ammatuna; Pau Montesinos; Miguel Angel Sanz
Journal:  Semin Oncol       Date:  2008-08       Impact factor: 4.929

6.  Clinical and biological features of acute promyelocytic leukemia patients developing retinoic acid syndrome during induction treatment with all-trans retinoic acid and idarubicin.

Authors:  Massimo Breccia; Roberto Latagliata; Ida Carmosino; Laura Cannella; Daniela Diverio; Anna Guarini; Maria Stefania De Propris; Maria Concetta Petti; Giuseppe Avvisati; Giuseppe Cimino; Franco Mandelli; Francesco Lo-Coco
Journal:  Haematologica       Date:  2008-10-22       Impact factor: 9.941

7.  Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin.

Authors:  Javier de la Serna; Pau Montesinos; Edo Vellenga; Chelo Rayón; Ricardo Parody; Angel León; Jordi Esteve; Juan M Bergua; Gustavo Milone; Guillermo Debén; Concha Rivas; Marcos González; Mar Tormo; Joaquín Díaz-Mediavilla; Jose D González; Silvia Negri; Elena Amutio; Salut Brunet; Bob Lowenberg; Miguel A Sanz
Journal:  Blood       Date:  2008-01-14       Impact factor: 22.113
  7 in total
  13 in total

1.  Comparing the epidemiology, clinical characteristics and prognostic factors of acute myeloid leukemia with and without acute promyelocytic leukemia.

Authors:  Geetanjali R Kamath; Douglas Tremblay; Alexander Coltoff; Jessica Caro; Guido Lancman; Sheena Bhalla; Vesna Najfeld; John Mascarenhas; Emanuela Taioli
Journal:  Carcinogenesis       Date:  2019-07-04       Impact factor: 4.944

2.  Management of hemostatic complications in acute leukemia: Guidance from the SSC of the ISTH.

Authors:  Tzu-Fei Wang; Robert S Makar; Darko Antic; Jerrold H Levy; James D Douketis; Jean M Connors; Marc Carrier; Jeffrey I Zwicker
Journal:  J Thromb Haemost       Date:  2020-12       Impact factor: 5.824

3.  Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid.

Authors:  Jae H Park; Baozhen Qiao; Katherine S Panageas; Maria J Schymura; Joseph G Jurcic; Todd L Rosenblat; Jessica K Altman; Dan Douer; Jacob M Rowe; Martin S Tallman
Journal:  Blood       Date:  2011-06-08       Impact factor: 22.113

4.  Class II-associated invariant chain peptide expression represents a novel parameter for flow cytometric detection of acute promyelocytic leukemia.

Authors:  Marvin M van Luijn; Theresia M Westers; Martine E D Chamuleau; S Marieke van Ham; Gert J Ossenkoppele; Arjan A van de Loosdrecht
Journal:  Am J Pathol       Date:  2011-09-09       Impact factor: 4.307

Review 5.  Curing all patients with acute promyelocytic leukemia: are we there yet?

Authors:  Muhamed Baljevic; Jae H Park; Eytan Stein; Dan Douer; Jessica K Altman; Martin S Tallman
Journal:  Hematol Oncol Clin North Am       Date:  2011-12       Impact factor: 3.722

6.  Emerging new approaches for the treatment of acute promyelocytic leukemia.

Authors:  Jae Park; Joseph G Jurcic; Todd Rosenblat; Martin S Tallman
Journal:  Ther Adv Hematol       Date:  2011-10

7.  A Canadian consensus on the management of newly diagnosed and relapsed acute promyelocytic leukemia in adults.

Authors:  M D Seftel; M J Barnett; S Couban; B Leber; J Storring; W Assaily; B Fuerth; A Christofides; A C Schuh
Journal:  Curr Oncol       Date:  2014-10       Impact factor: 3.677

8.  Treatment of acute promyelocytic leukemia with high white cell blood counts.

Authors:  C Kelaidi; L Adès; P Fenaux
Journal:  Mediterr J Hematol Infect Dis       Date:  2011-09-08       Impact factor: 2.576

9.  Pathogenesis and treatment of thrombohemorrhagic diathesis in acute promyelocytic leukemia.

Authors:  Anna Falanga; Laura Russo; Carmen J Tartari
Journal:  Mediterr J Hematol Infect Dis       Date:  2011-12-21       Impact factor: 2.576

10.  Absolute Circulating Leukemic Cells as a Risk Factor for Early Bleeding Events in Patients with Non-High-Risk Acute Promyelocytic Leukemia.

Authors:  Yanru Pei; Mingyue Shi; Juanjuan Song; Xiaona Niu; Shengjie Wei; Liurui Dou; Mengyu Xiao; Dan Li; Fangfang Xu; Yanliang Bai; Kai Sun
Journal:  Cancer Manag Res       Date:  2021-05-21       Impact factor: 3.989
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.